<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221650</url>
  </required_header>
  <id_info>
    <org_study_id>9232-01</org_study_id>
    <secondary_id>2000-023</secondary_id>
    <nct_id>NCT00221650</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients</brief_title>
  <acronym>ROCO2</acronym>
  <official_title>Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination of PEG interferon and ribavirin is the standard treatment of chronic hepatitis C.
      Efficacy of this treatment has never been evaluated in HCV-HIV infected patients, who have
      previously been treated with a first line anti-HCV treatment. The purpose of the study is to
      evaluate the combination PEG interferon alfa2a-ribavirin in HIV-infected patients with
      chronic hepatitis C pretreated with interferon alone or interferon combined with ribavirin.
      The patients receive a dose of 180 µg of PEGASYS once a week and 800 to 1200 mg/day of
      ribavirin (according to weight) for 48 weeks. Primary outcome of the study is a sustained
      virological response, defined as an undetectable HCV RNA level 24 weeks after the end of
      anti-HCV treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a sustained virological response, defined as an undetectable HCV RNA level</measure>
    <time_frame>24 weeks after the end of anti-HCV treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a virological response</measure>
    <time_frame>at weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of anti-HCV treatment on CD4 count and HIV RNA</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with histological response 24 weeks after the end of anti-HCV treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Treatment Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa2a</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C : Detectable HCV RNA, Previously treated with interferon or
             interferon combined with ribavirin, Elevated ALT level

          -  HIV infection (CD4&gt;250/µL, HIV RNA&lt;10 000 copies/ml) treated or not with
             antiretroviral therapy

          -  Signed informed consent

        Exclusion Criteria:

          -  Chronic hepatitis B

          -  Alcohol consumption&gt;40g/day

          -  Evidence of decompensated liver disease

          -  Hepatocellular carcinoma

          -  Other relevant disorders: organ transplantation, psychiatric or cardiovascular
             disease, poorly controlled diabetes, seizure disorders, hemoglobinopathy, autoimmune
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Neau, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pellegrin, 33076 Bordeaux Cedex, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Genevieve Chene, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Thiébaut R, Guedj J, Jacqmin-Gadda H, Chêne G, Trimoulet P, Neau D, Commenges D. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol. 2006 Aug 1;6:38.</citation>
    <PMID>16879756</PMID>
  </reference>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 12, 2007</last_update_submitted>
  <last_update_submitted_qc>June 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2007</last_update_posted>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>HCV infection</keyword>
  <keyword>HIV infection</keyword>
  <keyword>Treatment Failure</keyword>
  <keyword>PEG interferon</keyword>
  <keyword>Interferons/therapeutic use</keyword>
  <keyword>Interferon Alfa-2a/adverse effects</keyword>
  <keyword>Ribavirin/therapeutic use</keyword>
  <keyword>Ribavirin/adverse effects</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

